share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

諾瓦瓦克斯醫藥 | 4:持股變動聲明-高管 Dubovsky Filip
美股sec公告 ·  05/15 21:21
Moomoo AI 已提取核心訊息
On May 14, 2024, Novavax's President of R&D, Filip Dubovsky, completed a significant transaction involving the company's common stock. Dubovsky executed a sale of 47,312 shares at a price of $13.90 per share, resulting in a total market value of $657,636.80. Prior to this sale, Dubovsky acquired 19,652 shares through the exercise of derivative securities at a price of $6.97 each. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 38,953 shares of common stock.
On May 14, 2024, Novavax's President of R&D, Filip Dubovsky, completed a significant transaction involving the company's common stock. Dubovsky executed a sale of 47,312 shares at a price of $13.90 per share, resulting in a total market value of $657,636.80. Prior to this sale, Dubovsky acquired 19,652 shares through the exercise of derivative securities at a price of $6.97 each. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 38,953 shares of common stock.
2024年5月14日,Novavax的研發總裁菲利普·杜波夫斯基完成了一項涉及公司普通股的重大交易。杜波夫斯基以每股13.90美元的價格出售了47,312股股票,總市值爲657,636.80美元。在此次出售之前,杜波夫斯基通過行使衍生證券以每股6.97美元的價格收購了19,652股股票。這些交易之後,杜波夫斯基在Novavax的直接持有量爲38,953股普通股。
2024年5月14日,Novavax的研發總裁菲利普·杜波夫斯基完成了一項涉及公司普通股的重大交易。杜波夫斯基以每股13.90美元的價格出售了47,312股股票,總市值爲657,636.80美元。在此次出售之前,杜波夫斯基通過行使衍生證券以每股6.97美元的價格收購了19,652股股票。這些交易之後,杜波夫斯基在Novavax的直接持有量爲38,953股普通股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息